Prostate cancer, BRCA-mutated

From - A Hematology Oncology Wiki
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Page editor Section editor
Laura S. Graham, MD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, WA

Social-twitter-icon.png LauraGrahamMD
Ali Raza Khaki, MD
Stanford University
Palo Alto, CA

Social-twitter-icon.png arkhaki
1 regimens on this page
1 variants on this page

Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the main prostate cancer page for other regimens.

Metastatic castration-resistant

Rucaparib monotherapy

back to top


Study Years of enrollment Evidence
(TRITON2) 2017-NR Phase II (RT)

Note: this study is the basis of FDA approval; however, no dosing details are provided on and there are no published manuscripts to date.

Targeted therapy


  1. TRITON2: NCT02952534